AdvisorShares Pure U.S. Cannabis ETF Momentum Surges to 88.95 Amid Policy Shifts
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy TLRY?
Source: Benzinga
- Momentum Score Surge: The AdvisorShares Pure U.S. Cannabis ETF's momentum score skyrocketed from 24.75 to 88.95 in just over a week, reflecting strong market confidence in the cannabis sector, particularly following the Trump administration's policy shift to reclassify marijuana, which is expected to significantly enhance industry profitability.
- Profitability Enhancement: The reclassification allows companies like Tilray Brands Inc. to deduct standard business expenses, unlocking substantial cash flows that further drive investor interest in related stocks, contributing to a rally among the ETF's constituents in the new year.
- New Subsidiary Launch: Tilray has established Tilray Medical USA as its new medical subsidiary in response to the government's reclassification, aiming to tap into the “research-oriented national medical cannabis industry,” which will open new revenue streams and enhance market competitiveness.
- Favorable Market Trends: The AdvisorShares Cannabis ETF exhibits favorable price trends across short, medium, and long-term horizons, reflecting optimistic investor expectations for the future development of the cannabis industry, thereby solidifying its significance in investment portfolios.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 7.990
Low
8.50
Averages
9.57
High
10.00
Current: 7.990
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories' $23 Billion Acquisition of Exact Sciences Enhances Growth Potential
- Revenue Growth: Abbott Laboratories reported a 5.7% increase in revenue for 2025, reaching $44.3 billion, with adjusted earnings per share (EPS) rising 10% to $5.15, indicating recovery potential in its medical devices and pharmaceuticals sectors, although total revenue has yet to return to pre-pandemic peaks.
- Acquisition Deal: Abbott is finalizing its $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing oncology diagnostics market.
- Market Challenges: Despite strong growth in Abbott's medical devices and pharmaceuticals, sales in its nutrition and diagnostics segments have stagnated due to legal issues and FDA recalls related to FreeStyle Libre 3, leading to diminished investor interest in the stock.
- Future Outlook: Abbott anticipates adjusted EPS for 2026 to be in the range of $5.55 to $5.80, a 10% increase, while the cancer diagnostics market is projected to grow from $109.6 billion in 2024 to $155 billion by 2030, showcasing the company's long-term growth potential in the healthcare sector.
See More
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences
- Dividend Growth Record: Abbott Labs has raised its dividends for 54 consecutive years, with a 6.8% increase in 2023, reflecting its strong cash flow and profitability, which boosts investor confidence and solidifies its status as a 'Dividend King'.
- Acquisition-Driven Growth: Abbott is finalizing a $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing cancer testing market.
- Core Business Recovery: While Abbott's total revenue rose 5.7% to $44.3 billion in 2025 and adjusted EPS increased 10% to $5.15, challenges from lawsuits and recalls related to FreeStyle Libre 3 have impacted some segments, affecting overall market performance.
- Optimistic Market Outlook: Abbott's Volt Pulsed Field Ablation system has received FDA approval, potentially treating 12 million U.S. patients over 65 with atrial fibrillation, with expectations for this number to double in the next two decades, indicating significant growth potential in cardiac care.
See More
Tilray Brands Expands into CBD and Alcohol Markets
- Intensified Market Competition: Tilray Brands faces fierce competition in the marijuana market, where despite sales growth, profitability has not met Wall Street's expectations due to the ongoing presence of illegal drug sales, impacting the company's core business performance.
- Diversification Strategy: In response to market challenges, Tilray has begun expanding into new areas such as CBD and alcoholic beverages, which are logically adjacent, but the rapid transformation may introduce management risks and integration challenges.
- Equity Dilution Risk: Since 2021, Tilray's share count has increased by over 300%, primarily funded through stock sales, leading to dilution for existing shareholders and exposing the company to non-cash impairment losses.
- Warning Signs of Acquisition Strategy: Tilray has acquired 19 brands in a short period, and while diversification seems reasonable, the rapid acquisitions may lead to management errors, prompting investors to be cautious and wait for evidence of sustainable profits from its diversification strategy.
See More
Tilray Brands Stock Continues to Decline
- Stock Price Decline: Tilray Brands' stock has fallen 16% over the past year, plummeting 74% over the last three years and 97% over five years, reflecting investor pessimism about its future prospects.
- Growth and Execution Issues: Despite generating over $837 million in annual sales and becoming one of the largest cannabis companies globally, Tilray has faced ongoing cash burn and execution challenges during its rapid expansion.
- Dilution Impact: Since its U.S. market debut in 2018, Tilray's share count has increased by 495%, a significant factor contributing to its poor stock performance and diminishing shareholder returns.
- Weak Future Growth: Tilray's total net revenue grew by only 3% in Q2 of fiscal year 2026, with Wall Street projecting low-to-mid single-digit growth for the next fiscal year, leading to a significant decline in investor confidence.
See More
Tilray Shareholder Value Continues to Dwindle
- Shareholder Value Erosion: Since Tilray's U.S. market debut in July 2018, its share count has surged by 495%, leading to a significant erosion of shareholder value, with a 16% decline in stock price over the past year, 74% over three years, and a staggering 97% over five years.
- Cash Flow Issues: Despite generating over $837 million in annual sales, Tilray has consistently burned cash since going public, with only a 3% increase in net revenue in the second quarter, indicating severe pressure on profitability from illicit markets and high taxes.
- Bleak Market Outlook: Tilray's growth potential in the legal cannabis market appears limited, with Wall Street projecting only low-to-mid single-digit growth for the next fiscal year, leading to a significant decline in investor confidence regarding its future performance.
- Shift in Investment Recommendations: Analysts are advising investors to consider other stocks with greater potential, as Tilray did not make the current list of top investment opportunities, reflecting a pessimistic market sentiment towards its future development.
See More
Tilray Brands Faces Profitability Challenges Amid Aggressive Expansion
- Profitability Struggles: Tilray Brands has failed to achieve sustainable profits amid fierce competition and the ongoing illicit drug trade, resulting in a 99% drop in stock price from its all-time high, leading to investor disappointment regarding its future profitability.
- Diversification Strategy Risks: While Tilray seeks new revenue streams by expanding into alcoholic beverages, this strategy has yet to yield positive earnings and has instead increased financial risks for the company.
- Share Dilution Concerns: Tilray's aggressive brand acquisitions since 2021 have brought revenue growth, but the rising share count dilutes existing shareholders' equity, potentially complicating profit generation.
- High-Risk Investment Warning: Given the ongoing losses and aggressive acquisition strategy, Tilray is viewed as a high-risk investment, and investors are advised to remain on the sidelines until the company demonstrates its business model can support sustainable earnings.
See More
Abbott Laboratories' $23 Billion Acquisition of Exact Sciences Enhances Growth Potential
- Revenue Growth: Abbott Laboratories reported a 5.7% increase in revenue for 2025, reaching $44.3 billion, with adjusted earnings per share (EPS) rising 10% to $5.15, indicating recovery potential in its medical devices and pharmaceuticals sectors, although total revenue has yet to return to pre-pandemic peaks.
- Acquisition Deal: Abbott is finalizing its $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing oncology diagnostics market.
- Market Challenges: Despite strong growth in Abbott's medical devices and pharmaceuticals, sales in its nutrition and diagnostics segments have stagnated due to legal issues and FDA recalls related to FreeStyle Libre 3, leading to diminished investor interest in the stock.
- Future Outlook: Abbott anticipates adjusted EPS for 2026 to be in the range of $5.55 to $5.80, a 10% increase, while the cancer diagnostics market is projected to grow from $109.6 billion in 2024 to $155 billion by 2030, showcasing the company's long-term growth potential in the healthcare sector.
See More
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences
- Dividend Growth Record: Abbott Labs has raised its dividends for 54 consecutive years, with a 6.8% increase in 2023, reflecting its strong cash flow and profitability, which boosts investor confidence and solidifies its status as a 'Dividend King'.
- Acquisition-Driven Growth: Abbott is finalizing a $23 billion acquisition of Exact Sciences, which saw an 18% revenue increase to $3.2 billion in 2025, expected to enhance Abbott's diagnostics segment and strengthen its foothold in the rapidly growing cancer testing market.
- Core Business Recovery: While Abbott's total revenue rose 5.7% to $44.3 billion in 2025 and adjusted EPS increased 10% to $5.15, challenges from lawsuits and recalls related to FreeStyle Libre 3 have impacted some segments, affecting overall market performance.
- Optimistic Market Outlook: Abbott's Volt Pulsed Field Ablation system has received FDA approval, potentially treating 12 million U.S. patients over 65 with atrial fibrillation, with expectations for this number to double in the next two decades, indicating significant growth potential in cardiac care.
See More
Tilray Brands Expands into CBD and Alcohol Markets
- Intensified Market Competition: Tilray Brands faces fierce competition in the marijuana market, where despite sales growth, profitability has not met Wall Street's expectations due to the ongoing presence of illegal drug sales, impacting the company's core business performance.
- Diversification Strategy: In response to market challenges, Tilray has begun expanding into new areas such as CBD and alcoholic beverages, which are logically adjacent, but the rapid transformation may introduce management risks and integration challenges.
- Equity Dilution Risk: Since 2021, Tilray's share count has increased by over 300%, primarily funded through stock sales, leading to dilution for existing shareholders and exposing the company to non-cash impairment losses.
- Warning Signs of Acquisition Strategy: Tilray has acquired 19 brands in a short period, and while diversification seems reasonable, the rapid acquisitions may lead to management errors, prompting investors to be cautious and wait for evidence of sustainable profits from its diversification strategy.
See More
Tilray Brands Stock Continues to Decline
- Stock Price Decline: Tilray Brands' stock has fallen 16% over the past year, plummeting 74% over the last three years and 97% over five years, reflecting investor pessimism about its future prospects.
- Growth and Execution Issues: Despite generating over $837 million in annual sales and becoming one of the largest cannabis companies globally, Tilray has faced ongoing cash burn and execution challenges during its rapid expansion.
- Dilution Impact: Since its U.S. market debut in 2018, Tilray's share count has increased by 495%, a significant factor contributing to its poor stock performance and diminishing shareholder returns.
- Weak Future Growth: Tilray's total net revenue grew by only 3% in Q2 of fiscal year 2026, with Wall Street projecting low-to-mid single-digit growth for the next fiscal year, leading to a significant decline in investor confidence.
See More
Tilray Shareholder Value Continues to Dwindle
- Shareholder Value Erosion: Since Tilray's U.S. market debut in July 2018, its share count has surged by 495%, leading to a significant erosion of shareholder value, with a 16% decline in stock price over the past year, 74% over three years, and a staggering 97% over five years.
- Cash Flow Issues: Despite generating over $837 million in annual sales, Tilray has consistently burned cash since going public, with only a 3% increase in net revenue in the second quarter, indicating severe pressure on profitability from illicit markets and high taxes.
- Bleak Market Outlook: Tilray's growth potential in the legal cannabis market appears limited, with Wall Street projecting only low-to-mid single-digit growth for the next fiscal year, leading to a significant decline in investor confidence regarding its future performance.
- Shift in Investment Recommendations: Analysts are advising investors to consider other stocks with greater potential, as Tilray did not make the current list of top investment opportunities, reflecting a pessimistic market sentiment towards its future development.
See More
Tilray Brands Faces Profitability Challenges Amid Aggressive Expansion
- Profitability Struggles: Tilray Brands has failed to achieve sustainable profits amid fierce competition and the ongoing illicit drug trade, resulting in a 99% drop in stock price from its all-time high, leading to investor disappointment regarding its future profitability.
- Diversification Strategy Risks: While Tilray seeks new revenue streams by expanding into alcoholic beverages, this strategy has yet to yield positive earnings and has instead increased financial risks for the company.
- Share Dilution Concerns: Tilray's aggressive brand acquisitions since 2021 have brought revenue growth, but the rising share count dilutes existing shareholders' equity, potentially complicating profit generation.
- High-Risk Investment Warning: Given the ongoing losses and aggressive acquisition strategy, Tilray is viewed as a high-risk investment, and investors are advised to remain on the sidelines until the company demonstrates its business model can support sustainable earnings.
See More
